A Beginner Strength Training Workout for People on GLP-1s
Monday, April 6, 2026 – Tuesday, April 7 - Combat muscle loss with this 7-move routine.
Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy
Monday, April 6, 2026 – Tuesday, April 7 - Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.
GLP-1 agonist drugs show digestive side effects but may help fight infections
Monday, April 6, 2026 – Tuesday, April 7 - Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.
Dulaglutide or Tirzepatide? Worldwide Biopharma Changes
Saturday, April 4, 2026 – Sunday, April 5 - (MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
Wegovy Pill Demonstrated Greater Weight Loss Than Orforglipron and Lower Odds of Stopping Medication Due to Side Effects in a New Indirect Comparison to be Presented at Obesity Medicine Association 2026
Thursday, April 2, 2026 – Friday, April 3 - PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ -- Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25...
Foundayo vs. Wegovy: How Do the New Weight Loss Pills Compare?
Thursday, April 2, 2026 – Friday, April 3 - Their effectiveness also depends on what else you do when you take them.
Wegovy Maker Launches Lower-Cost Subscription Plans
Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.
Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more...
GLP-1 Receptor Agonist Use Tied to Delayed Surgical Wound Healing
Thursday, April 2, 2026 – THURSDAY, April 2, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in the April issue of Plastic and...
Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
Thursday, April 2, 2026 – Friday, April 3 - A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.
...
You Get a GLP-1! You Get a GLP-1! Everybody Gets a GLP-1!
Thursday, April 2, 2026 – Friday, April 3 - (MedPage Today) -- As a primary care physician and obesity board-certified specialist, I believe that GLP-1s are one of the best medical interventions of all time, right up there with vaccines, antibiotics, blood thinners, and statins. They really...